U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. For Industry
  3. FDA User Fee Programs
  4. Prescription Drug User Fee Amendments
  5. Exhibit 4-13 long description
  1. Prescription Drug User Fee Amendments

Exhibit 4-13 long description

For Product N, CMC, Clinical and P/T submissions were received 18 months before the complete submission, and additional Clinical and P/T submissions received 3 months prior. There were no requests for information (RFI) received and the application had an approvable action at 10 months. For Product O, the P/T submission was received 8 months prior to complete submission, the CMC submission 7 months prior and the Clinical submission triggered the PDUFA clock. Information requests for Clinical, CMC and P/T were sent out 2 months after complete submission and the application received an approval at 6months. For Product P, the P/T section was submitted 12 months early, the CMC 4 months early and the Clinical section completed the submission. Information requests were sent 2 months after complete submission. The P/T review was completed right after complete submission, the CMC at 2 months and the Clinical at 8.5 months. The application received an approval at 9 months. For product Q, the CMC and Clinical sections were submitted 1 month early and the P/T section started the PDUFA clock. Information requests were sent 1 month after submission and the reviews completed between 3 and 4 months after complete submission and an approval action taken at 4 months. For Product R, the P/T section was submitted 3.5 months early, the CMC section 2.5 months early and the Clinical section triggered the PDUFA clock. There was a clinical information request at 1.5 months and the application received an approvable at 6 months.

Back to Top